H.C. Wainwright reiterates Aclaris stock rating after trial miss

H.C. Wainwright reiterated a Buy rating and $16.00 price target on Aclaris Therapeutics (ACRS) despite its Phase 2 trial for bosakitug missing primary and secondary endpoints. The stock fell 8% to $3.60 post-announcement. Analysts remain bullish on ACRS's broader pipeline, with a Strong Buy consensus and price targets ranging from $4 to $16.

Original reporting
Published Nov 17, 2026, 12:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ACRS
Bearish
medium confidence
Mentioned
$ACRS
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ACRSBearishMed
01

Why it matters

The clinical miss is the immediate driver for sentiment, while the analyst framing shifts focus away from standalone bosakitug and toward the ATI-052 flagship candidate.

02

Market read

Traders get a near-term catalyst mix: a Phase 2 efficacy miss driving the selloff, plus a reiterated Buy that may limit downside if investors keep faith in the remaining pipeline.

03

What to watch

The article mentions robust target engagement and tolerability, which could support subgroup or combination strategies, but it does not specify any next-step plan or timeline.

Relevance 4/10Novelty 4/10Timing: after the Nov. 16 Phase 2 top-line release and same-day analyst reiteration

Background

H.C. Wainwright reiterates a Buy rating and $16 price target after Aclaris reported Phase 2 ADMIRATION top-line results for bosakitug in atopic dermatitis.

Company-level read

Ticker impact

$ACRSBearishMedium confidence
Context

Aclaris shares fell after Phase 2 ADMIRATION results for bosakitug missed endpoints, prompting H.C. Wainwright to reiterate Buy and a $16 target.

Expected impact

Likely continued volatility and downside bias as investors weigh the clinical miss against the unchanged pipeline thesis.

Evidence & confidence

The article centers on a Phase 2 miss and a sell-side stance split, with the reiterated Buy relying on the remaining flagship program rather than the failed asset.

Market effects

Reinforces risk-off sentiment for atopic dermatitis monoclonal antibody approaches after a Phase 2 miss, while keeping attention on alternative modalities in the same pipeline.

Limited, single-name biotech catalyst with no broader macro linkage.

Primarily US biotech sentiment; no direct global policy or cross-market linkage described.

Counterpoint

The reiterated Buy may be underweighting the probability that ATI-052 faces similar efficacy risk, given the trial’s biomarker engagement did not translate into endpoint success.

Key entities

  • Aclaris Therapeutics

    NASDAQ-listed biotech whose Phase 2 ADMIRATION trial for bosakitug missed endpoints; stock fell and sell-side views diverged.

  • bosakitug (ATI-045)

    Humanized anti-TSLP monoclonal antibody evaluated in Phase 2 ADMIRATION for atopic dermatitis.

  • ATI-052

    Bispecific construct viewed by H.C. Wainwright as the flagship candidate in Aclaris’s portfolio.

  • H.C. Wainwright

    Reiterated Buy rating and $16 price target after the Phase 2 trial results.

  • Wedbush

    Downgraded to Neutral and cut price target to $3 after the Phase 2 setback.

Related articles

$ACRSMedAI 8/10

Wedbush cuts Aclaris Therapeutics stock rating on trial miss

Wedbush downgraded Aclaris Therapeutics (ACRS) to Neutral, cutting its price target to $3.00 from $8.00 after a Phase 2 trial failure. The stock is down 13% over the past week. Wedbush expects Aclaris to shift focus to eosinophilic esophagitis but notes growing competition. Other analysts have mixed views on ACRS's pipeline and potential.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$ACRSHighAI 8/10

Aclaris stock falls after atopic dermatitis trial fails

Aclaris Therapeutics (NASDAQ:ACRS) shares dropped 6% after its Phase 2 ADMIRATION trial for atopic dermatitis treatment failed to meet primary and secondary endpoints. The trial evaluated bosakitug (ATI-045), which showed target engagement but did not improve Eczema Area and Severity Index scores. The company remains focused on other treatments, including modzatinib (ATI-2138) for lichen planus, with a Phase 2b trial underway.

$ACRSHighAI 8/10

Aclaris Therapeutics’ mAb fails in Phase II eczema trial

Aclaris Therapeutics' Phase II trial of bosakitug for atopic dermatitis failed to meet primary and secondary endpoints, though the drug showed target engagement. The company remains focused on other treatments, including modzatinib and ATI-052. The atopic dermatitis market is projected to grow to $21.5bn by 2033, with key players like Sanofi and AbbVie.